VRAX (Virax Biolabs Group) FCF Yield % : -124.55 (As of Apr. 06, 2025)

View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Virax Biolabs Group's Trailing 12-Month Free Cash Flow is $-5.28 Mil, and Market Cap is $4.24 Mil. Therefore, Virax Biolabs Group's FCF Yield % for today is -124.55%.

The historical rank and industry rank for Virax Biolabs Group's FCF Yield % or its related term are showing as below:

VRAX' s FCF Yield % Range Over the Past 10 Years
Min: -601.79 Med: -151.72 Max: -0.47
Current: -124.55

During the past 5 years, the highest FCF Yield % of Virax Biolabs Group was -0.47%. The lowest was -601.79%. And the median was -151.72%.

VRAX's FCF Yield % is ranked worse than
84.44% of 1497 companies
in the Biotechnology industry
Industry Median: -15.53 vs VRAX: -124.55

Virax Biolabs Group's FCF Margin % for the quarter that ended in Sep. 2024 was -43,340.00%.

Virax Biolabs Group FCF Yield % Historical Data

The historical data trend for Virax Biolabs Group's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group FCF Yield % Chart

Virax Biolabs Group Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

FCF Yield %

-40.30

-401.56

Virax Biolabs Group Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
FCF Yield %	Get a 7-Day Free Trial					-12.50	-34.83	-146.10	-336.92	-51.45

Competitive Comparison of Virax Biolabs Group's FCF Yield %

For the Biotechnology subindustry, Virax Biolabs Group's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Virax Biolabs Group's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Virax Biolabs Group's FCF Yield % falls into.

Save Embed

;

Save Embed

;

Virax Biolabs Group FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Virax Biolabs Group's FCF Yield % for the fiscal year that ended in Mar. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-7.411	/	1.845558
	=	-401.56%

Virax Biolabs Group's annualized FCF Yield % for the quarter that ended in Sep. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-2.167	*	2	/	8.42348
	=	-51.45%

Virax Biolabs Group FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Virax Biolabs Group FCF Yield % Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Virax Biolabs Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bo’Ness Road Newhouse, BioCity Glasgow, London, GBR, ML1 5UH

Website

https://www.viraxbiolabs.com

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.